Melanoma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Alerts
• Clinical Trials
• Forums

Pembrolizumab/Lenvatinib With and Without Responder-derived FMT in Relapsed/Refractory Melanoma
Condition:   PD-1 Refractory Advanced Melanoma Interventions:   Biological: Responder-Derived Fecal microbiota transplantation (R-FMT;   Drug: Pembrolizumab;   Drug: Lenvatinib Sponsors:   Diwakar Davar;   Merck Sharp & Dohme LLC;   Gateway for Cancer Research Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 8, 2023 Category: Research Source Type: clinical trials